home / stock / dbvt / dbvt news


DBVT News and Press, DBV Technologies S.A. From 03/07/24

Stock Information

Company Name: DBV Technologies S.A.
Stock Symbol: DBVT
Market: NASDAQ
Website: dbvtechnologies.com

Menu

DBVT DBVT Quote DBVT Short DBVT News DBVT Articles DBVT Message Board
Get DBVT Alerts

News, Short Squeeze, Breakout and More Instantly...

DBVT - DBV Technologies GAAP EPS of -$0.76, revenue of $15.7M

2024-03-07 17:18:53 ET More on DBV Technologies Seeking Alpha’s Quant Rating on DBV Technologies Historical earnings data for DBV Technologies Financial information for DBV Technologies Read the full article on Seeking Alpha For further details...

DBVT - DBV Technologies Reports Full Year 2023 Financial Results and Business Update

Montrouge, France, March 7, 2024 DBV Technologies Reports Full Year 2023 Financial Results and Business Update Advanced Viaskin™ Peanut clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old) Strengthened exec...

DBVT - Expected US Company Earnings on Thursday, March 7th, 2024

Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...

DBVT - DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024

Montrouge, France, March 4, 2024 DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on trea...

DBVT - DBV Technologies to Participate in Upcoming AAAAI 2024 Congress

Montrouge, France, February 20 2024 DBV Technologies to Participate in Upcoming AAAAI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 –NASDAQ: DBVT), a clinical-stage biopharmaceutical company focused on treatments for food allergies, today announced...

DBVT - Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023  

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 ...

DBVT - Wall Street Breakfast Podcast: DBV's Toddler Peanut Allergy Therapy Shows Positive Results

2023-11-10 06:44:30 ET Summary DBV Technologies reports positive results for peanut allergy therapy in toddlers. Meta Platforms signs a deal with Tencent to sell a lower-priced version of its VR headset in China. BlackRock plans to create an Ethereum ETF, according to a filing...

DBVT - DBV reports positive Phase 3 data for peanut allergy therapy in toddlers

2023-11-09 18:06:47 ET More on DBV Technologies DBV Technologies S.A. (DBVT) Q3 2023 Earnings Call Transcript Equitable Holdings Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on DBV Technologies Historical earnings data for DBV Technologies ...

DBVT - DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin(TM) Peanut in Toddlers

Montrouge, France, November 9, 2023 DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers Viaskin Peanut showed improvement between months 12 and 24 of treatment across all efficacy p...

DBVT - Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010...

Previous 10 Next 10